| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.05. | Biopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role? | ||
| 14.05. | FDA floats possible approach to repurpose approved drugs under new uses | ||
| 14.05. | Sun recalls US chemotherapy batch, citing glass particle contamination concerns | ||
| 14.05. | Bora snaps up MacroGenics' manufacturing, CDMO operations for up to $127.5M | ||
| 13.05. | BeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphoma | ||
| 13.05. | As Trump arrives in China, Big Pharma CEOs are notably absent | ||
| 13.05. | Haleon tackles sports injuries with latest soccer play | ||
| 13.05. | BeOne Medicines' Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions' | ||
| 13.05. | Takeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drive | ||
| 13.05. | Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies | ||
| 13.05. | Merck KGaA looks to M&A to bolster its 'rather slim' pipeline | ||
| 12.05. | FDA Commissioner Marty Makary to resign, capping turbulent tenure: report | ||
| 12.05. | Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report | ||
| 12.05. | Alkermes' Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisition | ||
| 12.05. | As public vaccine criticism quiets, RFK Jr. keeps safety inquiries running in background: NYT | ||
| 12.05. | Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu | ||
| 12.05. | Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition | ||
| 12.05. | EU advances scheme to bolster manufacturing autonomy, avert drug shortages | ||
| 12.05. | Bicara Therapeutics hires Replimune, Sanofi alum as chief commercial officer | ||
| 11.05. | CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion | ||
| 11.05. | Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer | ||
| 11.05. | Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan | ||
| 11.05. | OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint | ||
| 11.05. | Eli Lilly shoots for health in new Caitlin Clark ad campaign | ||
| 08.05. | Targeted Protein Degradation and Novel Modalities: Getting on the Frontline |